 Operational Highlights
• Period of substantive and encouraging development across 
drug portfolio taking lead compounds to significant value 
inflection points;
• Phase l/ll Clinical Trial of VAL201 has continued to demonstrate 
high safety and tolerability and has received MHRA approval 
to extend and expand the scope of the clinical trial to treat 
prostate cancer;
• Completion of VAL401’s Phase II Clinical Trial in patients  
with lung cancer - with trial data offering palliative stage 
patients an improvement in symptoms alongside improved 
survival prospects;
• Period saw the optimized, commercially viable, 2
nd
 generation 
development of the VAL101molecule derived from ValiRx’s 
proprietary GeneICE platform to shut down rebellious genes 
causing cancer and potentially some neurological disorders – 
preparation is underway for the compound’s entry into the clinic;
• VAL301 is in late pre-clinical phase initially for the treatment of 
the gynaecological condition, endometriosis – a reformulation 
of VAL201, which pre-clinical studies suggest does not 
compromise bone density or fertility. Final laboratory tests 
are underway prior to advancing the VAL301 compound into 
additional toxicology and then clinical trials;
• Patent protection and portfolio coverage was extended for 
VAL201 and VAL401 during the period with US patent granted 
for VAL201 in Q1 2018.
Financial Highlights 
• Four Placings during the period raising £3.07m to advance  
the clinical trial of VAL201 and for the pre-clinical progress  
of other programmes;
• Marked 36.4% reduction in total comprehensive loss for  
the year to £3.02m (2016: Loss £4.75m) reflecting decrease  
in clinical trial expenditure on medicinal products;
• Loss per share from continuing operations of 1.90p  
(2016: Loss 8.54p);
• Cash and cash equivalents as at 31 December 2017 of £701,410  
(2016: £560,763).
Strategic Report
 
Highlights 01
Chairman’s Statement 02 
How we Create Value 04 
Our Products 06
Marketplace 08 
Licensing Collaborations 10
Therapeutics 12
Chief Executive’s Report 14
Risks and Uncertainties 16
Governance
 
Board of Directors 18 
Directors’ Report 20
Independent Auditors’ Report 22
Financial Statements
 
Consolidated Statement 
of Comprehensive Income 26
Consolidated Statement 
of Financial Position 27
Company Statement  
of Financial Position 28
Consolidated Statement 
of Changes in Equity 29
Company Statement of 
Changes in Equity 30
Consolidated Statement  
of Cash Flows 31
Notes to the Consolidated 
Statement of Cash Flows 32
Notes to the Consolidated  
Financial Statements 33
View more on our website  
www.valirx.com
ValiRx plc Annual Report and Accounts 2017 01
Strategic Report
Governance
Financial Statements
